ARD-2051

ARD-2051 is a selective and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 exhibits effective anti-tumor activity in VCaP xenograft mice model. ARD-2051 can be used for the research of prostate cancer (Pink: AR ligand.


Cat. No.: EX-A12444	Purity: >98%

	Chemical structure of ARD-2051

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	1950	Inquire
250mg	2550	3-4 weeks
500mg	3650	3-4 weeks
1g	5980	3-4 weeks
2g	7980	3-4 weeks

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	2632305-17-8
Purity	>98%
Formula	C43H45ClN8O5
Mol Weight	789.321
Color	Light yellow to yellow
State	solid
Solubility	Soluble in DMSO
Shelf Life	>3 years if stored properly
Storage	Powder -20℃, 3 years; 4℃, sealed storage , protect from light, 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Han X, et al. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. J Med Chem. 2023 Jul 13;66(13):8822-8843.
CoA	CoA of ARD-2051

Smiles:	C[C@H]1CC2(CN1C3=CC(Cl)=C(C#N)C=C3)CCN(CC2)C4=CC=C(C(=O)N5CCN(CC5)C6CN(C6)C=7C=C8C(=CC7)C(=O)N(C8=O)C9C(=O)NC(=O)CC9)C=C4


		Search